- Home
- VYGR vs FULC Comparison
VYGR vs FULC Comparison
Compare VYGR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- FULC
- Stock Information
- Founded
- VYGR 2013
- FULC 2015
- Country
- VYGR United States
- FULC United States
- Employees
- VYGR N/A
- FULC N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- VYGR Health Care
- FULC Health Care
- Exchange
- VYGR Nasdaq
- FULC Nasdaq
- Market Cap
- VYGR 222.9M
- FULC 210.9M
- IPO Year
- VYGR 2015
- FULC 2019
- Fundamental
- Price
- VYGR $3.41
- FULC $2.93
- Analyst Decision
- VYGR Strong Buy
- FULC Hold
- Analyst Count
- VYGR 9
- FULC 8
- Target Price
- VYGR $14.86
- FULC $6.57
- AVG Volume (30 Days)
- VYGR 360.5K
- FULC 454.3K
- Earning Date
- VYGR 03-11-2025
- FULC 05-12-2025
- Dividend Yield
- VYGR N/A
- FULC N/A
- EPS Growth
- VYGR N/A
- FULC N/A
- EPS
- VYGR N/A
- FULC N/A
- Revenue
- VYGR $80,001,000.00
- FULC $80,000,000.00
- Revenue This Year
- VYGR N/A
- FULC N/A
- Revenue Next Year
- VYGR $23.46
- FULC N/A
- P/E Ratio
- VYGR N/A
- FULC N/A
- Revenue Growth
- VYGR N/A
- FULC 2752.05
- 52 Week Low
- VYGR $3.56
- FULC $2.78
- 52 Week High
- VYGR $10.66
- FULC $10.13
- Technical
- Relative Strength Index (RSI)
- VYGR 28.74
- FULC 37.74
- Support Level
- VYGR $3.58
- FULC $3.00
- Resistance Level
- VYGR $3.96
- FULC $3.35
- Average True Range (ATR)
- VYGR 0.25
- FULC 0.18
- MACD
- VYGR -0.01
- FULC 0.02
- Stochastic Oscillator
- VYGR 2.60
- FULC 24.78
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.